September 26, 2024 09:00 PM EDT
R&D
Special

End­points 11 win­ner Xaira Ther­a­peu­tics: Biotech’s largest AI bet with A-list back­ers

Andrew Dunn

Senior Biopharma Correspondent

↑
  • CEO Marc Tessier-Lav­i­gne
  • To­tal raised More than $1 bil­lion in com­mit­ted cap­i­tal
  • Head­quar­ters South San Fran­cis­co, CA

David Bak­er’s Seat­tle …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times